caffeine speeds recovery from anesthesia

IMPACT OF CAFFIENE ON EMERGENCE FROM ANESTHESIA AND DISCHARGE CRITERIA IN DAY CASE SURGERIES: A PROSPECTIVE RANDOMIZED DOUBLE-BLIND PLACEBO CONTROLLED TRIAL

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

PACTR

Registry ID

PACTR202101897491424

Enrollment

Registered

2021-01-15

Start date

2020-05-10

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anaesthesia

Interventions

placebo control

caffeine group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: normotensive patients aged 18-60 years (ASA physical status I or II, BMI 18-35 Kg/m2) scheduled for elective day case surgeries under general anaesthesia

Exclusion criteria

Exclusion criteria: • Pregnant patients, • Breastfeeding • Severe visual or auditory impairment • Mental disorders or cognitive dysfunction. • Cardiac, liver, neuromuscular, endocrine or kidney diseases, • abnormal electrocardiogram findings • Peptic ulcer disease, gastroesophageal reflux disease or malabsorption diseases. • Severe anxiety. • History of epilepsy, antipsychotic, antidepressant medications or any other neurological problem. • Sensitivity to caffeine. • Use of caffeine and other caffeine containing tablets or beverages or methyl xanthines within 2 days prior to the study. • Cigarette smokers and alcohol and/or drug abusers.

Design outcomes

Primary

Measure	Time frame
the elapsed time after T0 until opening the eyes either spontaneously or upon verbal request repeated every 60 seconds by a blinded investigator.	—

Secondary

Measure	Time frame
• The ET isoflurane, BIS level and minute volume will be observed continuously starting with isoflurane switching off till extubation. The last values before extubation will be recorded. ;• Mean arterial pressure, and heart rate ;• extubation time ;• The elapsed time from T0 to the time the patient stated his/her full name (commands will be given every 20 s by a blinded investigator).;Adverse events: the occurrence of pain, nausea and/or vomiting, shivering, seizures, agitation, and any other adverse event. The visual analog scale (VAS), grading 0 to 10 cm, will be used to evaluate pain (0 = no pain to 10= the most pain I have ever felt) and nausea (0 = no nausea to 10 = as nauseous as I have ever been) during recovery. Pain requiring rescue medications (VAS>4) will be recorded. Agitation will be screened by modified Richmond sedation score	—

Measure

Time frame

• The ET isoflurane, BIS level and minute volume will be observed continuously starting with isoflurane switching off till extubation. The last values before extubation will be recorded. ;• Mean arterial pressure, and heart rate ;• extubation time ;• The elapsed time from T0 to the time the patient stated his/her full name (commands will be given every 20 s by a blinded investigator).;Adverse events: the occurrence of pain, nausea and/or vomiting, shivering, seizures, agitation, and any other adverse event. The visual analog scale (VAS), grading 0 to 10 cm, will be used to evaluate pain (0 = no pain to 10= the most pain I have ever felt) and nausea (0 = no nausea to 10 = as nauseous as I have ever been) during recovery. Pain requiring rescue medications (VAS>4) will be recorded. Agitation will be screened by modified Richmond sedation score

—

Countries

Egypt

Contacts

Public Contactkhaled gaballah

lecturer of anesthesia

khgaballah@gmail.com00201016009073

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026